EXOSC2 and plasma cell myeloma: The difference in severity of functional and molecular consequences that we observe for the rrp4-M68T and rrp4-G226D mutant models may partially explain the differences in disease pathology between SHRF patients with the mutation EXOSC2 G198D and the multiple myeloma patient with the mutation EXOSC2 M40T.